MAHARASHTRA, India Wockhardt has announced that the company will be launching a generic version of Pfizer’s Zoloft (sertraline) tablets in the United States. The Food and Drug Administration has approved the company for marketing the tablets containing 25 mg, 50 mg and 100 mg sertraline hydrochloride, which is used for treating depression.
“With over a dozen new product launches in the last twelve months and the recent acquisition of Morton Grove Pharmaceuticals, Wockhard’s U.S. business has been making significant progress” said Wockhardt chairman Habil Khorakiwala. “We are continuing to strengthen the U.S. operations by filing several [applications], including technologically challenging products.”
The total market for Sertraline tablets in the US is $1.1 billion, equivalent to over 1.4 billion tablets, according to IMS Health data.